Guan X, Wang L, Cao Y, Shi F, Xu H, Ding J, Wu M, Li H. A Erratum on Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China. Health Decision. 2023;1. doi:10.54844/hd.2023.0498